VanEck Pharmaceutical ETF
PPH
127 hedge funds and large institutions have $713M invested in VanEck Pharmaceutical ETF in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 44 increasing their positions, 47 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
4% more capital invested
Capital invested by funds: $685M → $713M (+$28.7M)
0.9% less ownership
Funds ownership: 115.5% → 114.6% (-0.9%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
6% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 47
2% less funds holding
Funds holding: 129 → 127 (-2)
93% less call options, than puts
Call options by funds: $3.59M | Put options by funds: $53.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$57.1M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$45.4M |
| 3 |
RAM
Revere Asset Management
Dallas,
Texas
|
+$15.1M |
| 4 |
Morgan Stanley
New York
|
+$10.3M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$8.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$75.8M |
| 2 |
Jane Street
New York
|
-$26.2M |
| 3 |
HW
Hamilton Wealth
Encino,
California
|
-$11.7M |
| 4 |
VV
Verity & Verity
Beaufort,
South Carolina
|
-$11.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.5M |
PPH Hedge Fund Activity: Q3 2025 in Review
127 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2025, worth a combined $713M — up 4.2% from $685M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PPH and 15 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 44 added.
The largest buyer was Citigroup, adding an estimated $57.1M. The largest seller was Goldman Sachs, cutting an estimated $75.8M.
- 127 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2025, down from 129 in Q2 2025.
- Funds reported $713M of VanEck Pharmaceutical ETF stock for Q3 2025, up 4.2% quarter-over-quarter.
- 15 funds opened new VanEck Pharmaceutical ETF positions in Q3 2025 and 16 closed out, a net change of -1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2025 was Citigroup, an estimated $57.1M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2025 was Goldman Sachs, an estimated $75.8M sold.
Based on aggregated 13F filings for Q3 2025.